Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
Completed
10 enrolled
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed
57 enrolled
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Phase 1 Completed
58 enrolled 17 charts
Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
Phase 2 Completed
26 enrolled 14 charts
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase 1/2 Completed
70 enrolled 26 charts
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Phase 1 Completed
77 enrolled
AZD8055 for Adults With Recurrent Gliomas
Phase 1 Completed
22 enrolled
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Phase 1/2 Completed
31 enrolled
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Phase 2 Completed
4 enrolled 9 charts
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
Phase 1 Completed
40 enrolled
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
Phase 1 Completed
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Phase 1 Completed
35 enrolled
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Phase 1 Completed
56 enrolled
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled
Bevacizumab for Recurrent Malignant Glioma
Phase 2 Completed
88 enrolled 11 charts
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Caspofungin Acetate in Treating Children With Fever and Neutropenia
Phase NA Completed
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
Phase 2 Completed
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
Phase 1/2 Completed
Study of @neWorld: A Virtual Community for Children With Cancer
Phase 1/2 Completed
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
Phase NA Completed
30 enrolled
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
Phase 1 Completed
18 enrolled
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
Phase 2 Completed
77 enrolled
Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J
Completed
23 enrolled
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
Phase 1 Completed
24 enrolled